griffithsin
Botanicalexperimental
Griffithsin is a protein isolated from the red algae Griffithsia. It has a 121-amino acid sequence which exhibits a Jacalin-like lectin fold. Several structures of this protein have been solved by X-ray crystallography and deposited in the PDB. It has been shown in vitro to be a highly potent HIV entry inhibitor. It is currently being investigated as a potential microbicide for use in the prevention of the transmission of HIV. — Wikipedia
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2017 (NCT02875119)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetUnclear
Unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGriffithsin ↗
Also known as
- griffithsin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04032717 | Phase 1 | Jul 10, 2019 | Intrucept Biomedicine LLC, National Institute of Allergy and Infectious Diseases (NIAID), University of Pittsburgh |
| NCT02875119 | Phase 1 | Jan 1, 2017 | Population Council |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Intrucept Biomedicine LLC | For profit | 1 | 0 | 1 | 2019 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2019 |
| Population Council | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2019 |
4 organizations
Page 1 / 1